Company intelligence / Profile preview

Steba Laboratories

Luxembourg

Ownership: Private
Employees: ~53
Development stage: Other

Overview

Steba Biotech has achieved EMA approval and Israel/Mexico market authorization for a photodynamic therapy (Padeliporfin, TOOKAD) in early-stage prostate cancer; pivotal Phase 3 study ongoing in upper tract urothelial cancer (UTUC) in the US. Clinical trials have shown significantly reduced progression to invasive treatment and preservation of urinary and erectile function versus active surveillance in prostate cancer.

Therapeutic areas: Oncology
Modalities: Small moleculeDevice
Industry: Biotech

Partnerships

Weizmann Institute of Science

Beyond the preview

Go deeper on Steba Laboratories.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Steba Laboratories.

Explore the full profile